Paeds SAQs · genetics-dysmorphology-and-metabolism
Turner syndrome — formative SAQs
Formative SAQs on recognising Turner syndrome across the four age-based presentations, confirming the karyotype, classifying the karyotype and its management implications, initiating growth-hormone and timed-oestrogen therapy, and running the cardiovascular and gonadoblastoma surveillance.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A 13-year-old girl is referred for short stature and absent breast development. She is on the first centile for height, with a low posterior hairline, neck webbing, cubitus valgus, and a soft left infraclavicular murmur. Her bone age is delayed. FSH is markedly elevated and oestradiol is low. A peripheral blood karyotype returns 45,X. [2] [1]
a) Explain the pathophysiology underlying her short stature and skeletal features, naming the specific gene responsible and its chromosomal location. (2 marks) [2]
b) Outline the baseline investigations you will arrange now that the karyotype is confirmed, naming the cardiovascular imaging that defines the aortic risk and two further organ systems requiring screening. (3 marks) [1] [8]
c) Describe the growth-hormone and oestrogen-replacement plan, including the rationale for the timing of each and the approximate adult-height gain expected from growth hormone. (3 marks) [3] [1]
d) Explain why the aortic dissection surveillance thresholds are lower in Turner syndrome than in the general population, and name two clinical features that heighten the dissection risk. (2 marks) [1] [8]
References4ShowHide
- [1]Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol, 2017.PMID 28705803
- [2]Sybert VP, McCauley E. Turner's syndrome. N Engl J Med, 2004.PMID 15371580
- [3]Stephure DK Impact of growth hormone supplementation on adult height in turner syndrome. J Clin Endocrinol Metab, 2005.PMID 15784709
- [8]Trolle C, Mortensen KH, Hjerrild BE, et al. Clinical care of adult Turner syndrome--new aspects. Pediatr Endocrinol Rev, 2012.PMID 22946288